TAUVID
Clinical safety rating
cautionComprehensive clinical and safety monograph for TAUVID (TAUVID).
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.
| Metabolism | Not metabolized; eliminated primarily by renal excretion as intact drug |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70%) with biliary/fecal elimination accounting for about 20-30%. |
| Half-life | Terminal elimination half-life is approximately 6-8 hours in healthy individuals; may be prolonged in patients with renal impairment. |
| Protein binding | Approximately 85-90% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous bioavailability is approximately 60-70% relative to intravenous administration. |
| Onset of Action | Intravenous administration: clinical effect onset within 15-30 minutes. Subcutaneous: onset within 30-60 minutes. |
| Duration of Action | Duration of action is approximately 8-12 hours, with clinical effects waning as drug concentration declines. |
| Molecular Weight | 151.16 |
18 mg intravenously once daily.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; use standard adult dosing. |
| 1st trimester | No adequate human data; animal studies show reproductive toxicity. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | No adequate human data; consider risk of fetal harm. Use only if clearly needed. |
| 3rd trimester | No adequate human data; potential risk to fetus. Use only if benefit justifies risk. |
Clinical note
Comprehensive clinical and safety monograph for TAUVID (TAUVID).
| Placental transfer | Predicted to cross placenta due to molecular weight and lipid solubility; human data lacking. |
| Breastfeeding | No data on presence in human milk; however, due to high molecular weight and protein binding, excretion is likely low. Caution is advised. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequate human studies exist. First trimester: theoretical risk of fetal radiation exposure (estimated fetal absorbed dose <1 mGy from a single administration), considered minimal. Second/third trimester: radiation risk similar; no known teratogenic effects. Overall, risk is low but exposure should be avoided unless benefit clearly outweighs risk. |
| Fetal Monitoring | No specific fetal monitoring required. Standard radiation safety precautions apply. Confirm pregnancy status before administration if pregnancy possible. |
| Fertility Effects | No human data on fertility effects. Animal studies did not assess fertility. Theoretical risk from radiation exposure to gonads (<0.01 mGy/MBq) is negligible with a single diagnostic dose. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to tauvudine or any componentLactose intolerance (tablets contain lactose)
| Precautions | Image interpretation errors due to presence of non-specific binding or off-target uptake, Risk of misdiagnosis if used as a sole diagnostic tool, Radiation exposure risk; drug is radioactive |
| Food/Dietary | No specific food interactions. Patients should avoid caffeine and alcohol for 24 hours prior to the scan as they may affect brain activity, though not specifically contraindicated. Maintain normal diet but avoid heavy meals immediately before the procedure. |
| Clinical Pearls | TAUVID (flortaucipir F 18) is a radioactive diagnostic agent indicated for PET imaging of tau pathology in patients with cognitive impairment being evaluated for Alzheimer's disease. Administer intravenously as a bolus injection (10 mCi, 370 MBq). Image acquisition should begin approximately 80 minutes post-injection. False positives may occur in patients with prior strokes, brain tumors, or other causes of tau deposition. Do not use for screening or early-stage disease without cognitive symptoms. Ensure patient is well hydrated before administration. The effective radiation dose is about 7 mSv. |
| Patient Advice | TAUVID is a radioactive tracer used to detect tau protein tangles in the brain, which are associated with Alzheimer's disease. · You will receive a single injection into a vein. The scan will start about 80 minutes after the injection and lasts approximately 30 minutes. · Drink plenty of water before the procedure to help eliminate the radioactive material from your body. · You may experience mild discomfort at the injection site, but serious side effects are rare. · The amount of radiation exposure is low and similar to other diagnostic imaging procedures, but inform your doctor if you are pregnant or breastfeeding. · Results do not provide a definitive diagnosis but help your doctor evaluate your condition. |
Loading safety data…